menu

Targeting cardiac energetics with cardiac mitotrope in nonobstructive HCM

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Targeting cardiac energetics with cardiac mitotrope in nonobstructive HCM

Martin Maron at the ACC24 about IMPROVE HCM
Restart
Resume
Choose a format
Media formats available:
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Comments
  • Overview

    ACC.24 - There is an unmet treatment need for nonobstructive hypertrophic cardiomyopathy (nHCM). Martin Maron shares the results of IMPROVE-HCM, which evaluated the efficacy and safety of the novel cardiac mitotrope ninerafaxstat in nHCM.

  • Educational information

    This video was recorded in response to a presentation at the Congress of the American College of Cardiology (ACC) 2024.

  • Faculty

    Martin Maron, MD is Director of the Hypertrophic Cardiomyopathy Center Lahey Medical Center and Hospital in Burglington, MA, US. He also is Board Director at the Chanin T. Mast Hypertrophic Cardiomyopathy Center in Morristown Medical Center, Morristown, NJ, VS.

  • Disclaimer

    This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.

    Read our summary of IMPROVE-HCM

    Release date: 22 April 2024

Facebook Comments

Recommended
Details
Presenters
Comments
  • Overview

    ACC.24 - There is an unmet treatment need for nonobstructive hypertrophic cardiomyopathy (nHCM). Martin Maron shares the results of IMPROVE-HCM, which evaluated the efficacy and safety of the novel cardiac mitotrope ninerafaxstat in nHCM.

  • Educational information

    This video was recorded in response to a presentation at the Congress of the American College of Cardiology (ACC) 2024.

  • Faculty

    Martin Maron, MD is Director of the Hypertrophic Cardiomyopathy Center Lahey Medical Center and Hospital in Burglington, MA, US. He also is Board Director at the Chanin T. Mast Hypertrophic Cardiomyopathy Center in Morristown Medical Center, Morristown, NJ, VS.

  • Disclaimer

    This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.

    Read our summary of IMPROVE-HCM

    Release date: 22 April 2024

Facebook Comments

Schedule25 May 2024